Atransen Pharma Ltd. has entered into a Memorandum of Understanding (MOU) with Fujita Health University, Sumitomo Heavy Industries, Ltd. (SHI), Stella Pharma Corporation, and Fujita Corporation to advance research and development in Boron Neutron Capture Therapy (BNCT) for deep-seated tumor treatment.
BNCT is a novel cancer treatment that selectively targets cancer cells while minimizing damage to surrounding healthy tissue. Historically, its application has been limited to tumors located within 6–8 cm from the body surface due to challenges in delivering neutrons safely and effectively to deeper tissues. This collaboration aims to overcome these limitations by leveraging the unique strengths of each participating organization:
Atransen Pharma: Developing and providing technologies to maintain BNCT drug concentrations within cancer cells.
Fujita Health University: Supplying highly specialized personnel based on its extensive clinical research experience in effective cancer treatments.
Sumitomo Heavy Industries: Offering cutting-edge technology grounded in its extensive experience in developing and manufacturing BNCT equipment.
Stella Pharma: Contributing knowledge and experience in pharmaceutical research and development for the creation and manufacturing of BNCT drugs.
Fujita Corporation: Constructing facilities using low-activation concrete suitable for BNCT equipment, drawing on its extensive experience in hospital construction.
By integrating these diverse areas of expertise, the partnership seeks to expand BNCT’s applicability to deeper-seated tumors, thereby broadening treatment options for patients with challenging cancer types. The collaborative efforts will focus on research and development leading to joint clinical trials, with the ultimate goal of enhancing cancer treatment modalities.
Atransen Pharma is committed to contributing to the advancement of cancer therapy through this strategic collaboration, aiming to bring innovative and effective treatments to patients in need.
Sumitomo Heavy Industries, Ltd.
https://www.shi.co.jp/english/info/2024/6kgpsq0000003on9.html
The NIKKEI、Nihon Keizai Shimbun Inc.
https://www.nikkei.com/article/DGXZQOUC092LX0Z00C24A7000000/